Chelating agents and their use in radiopharmaceutical sciences

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 11, 2011, Pages 968-983

  Wangler B ^a   Schirrmacher, R ^b   Bartenstein, P ^a   Wangler C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Biodistribution; Chelator; Complex stability; Medicinal application; Radiometal nuclides

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM 225; CHELATING AGENT; COPPER 64; COPPER 67; CYCLAM; GADOTERATE MEGLUMINE; GALLIUM 67; GALLIUM 68; INDIUM 111; INDIUM-PENTETATE; LUTETIUM; LUTETIUM 177; METAL ION; NITRILOTRIACETATE COPPER; PENTETATE INDIUM IN 111; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 86; YTTRIUM 90;

CHELATION; CHEMISTRY; COMPLEX FORMATION; CONJUGATION; COORDINATION; DELIVERY; MOLECULAR IMAGING; REVIEW;

CHELATING AGENTS; HUMANS; MOLECULAR IMAGING; MOLECULAR STRUCTURE; RADIOPHARMACEUTICALS;

EID: 80052203479     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711797068445     Document Type: Review

References (138)

1. Brown, K.C. Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications. Curr. Pharm. Des., 2010, 16, 1040-54.
2. Mezo, G.; Manea, M. Receptor-Mediated Tumor Targeting Based on Peptide Hormones. Exp. Opinion Drug Del., 2010, 7, 79-96.
3. Wu, C. Diabodies: Molecular Engineering and Therapeutic Applications. Drug News Perspect., 2009, 22, 453-8.
4. Kontermann, R.E. Recombinant Bispecific Antibodies for Cancer Therapy. Acta Pharmacol. Sin., 2005, 26, 1-9.
5. Milenic, D.E.; Brady, E.D.; Brechbiel, M.W. Antibody-Targeted Radiation Cancer Therapy. Nature Rev. Drug Disc., 2004, 3, 488-98.
6. De Leon-Rodriguez, L.M.; Kovacs, Z. The Synthesis and Chelation Chemistry of Dota-Peptide Conjugates. Bioconjug. Chem., 2008, 19, 391-402.
7. Lee, S.; Xie, J.; Chen, X.Y. Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis. Chem. Rev., 2010, 110, 3087-111.
8. Fichna, J.; Janecka, A. Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging. Bioconjug. Chem., 2003, 14, 3-17.
9. Boswell, C.A.; Brechbiel, M.W. Development of Radioimmunotherapeutic and Diagnostic Antibodies: An inside-out View. Nucl. Med. Biol., 2007, 34, 757-78.
10. Liu, S. Bifunctional Coupling Agents for Radiolabeling of Biomolecules and Target-Specific Delivery of Metallic Radionuclides. Adv. Drug Del. Rev., 2008, 60, 1347-70.
11. Mewis, R.E.; Archibald, S.J. Biomedical Applications of Macrocyclic Ligand Complexes. Coord. Chem. Rev., 2010, 254, 1686-712.
12. Lattuada, L.; Barge, A.; Cravotto, G.; Giovenzana, G.B.; Tei, L. The Synthesis and Application of Polyamino Polycarboxylic Bifunctional Chelating Agents. Chem. Soc. Rev., 2011, 40, 3019-49.
13. Liu, S. The Role of Coordination Chemistry in the Development of Target-Specific Radiopharmaceuticals. Chem. Soc. Rev., 2004, 33, 445-61.
14. Nayak, T.K.; Brechbiel, M.W. Radioimmunoimaging with Longer- Lived Positron-Emitting Radionuclides: Potentials and Challenges. Bioconjug. Chem., 2009, 20, 825-41.
15. Woods, M.; Kovacs, Z.; Sherry, A.D. Targeted Complexes of Lanthanide(III) Ions as Therapeutic and Diagnostic Pharmaceuticals. J. Supram. Chem., 2002, 2, 1-15.
16. Parry, J.J.; Kelly, T.S.; Andrews, R.; Rogers, B.E. In vitro and in vivo Evaluation of Cu-64-Labeled Dota-Linker-Bombesin(7-14) Analogues Containing Different Amino Acid Linker Moieties. Bioconjug. Chem., 2007, 18, 1110-7.
17. Mease, R.C.; Lambert, C. Newer Methods of Labeling Diagnostic Agents with Tc-99m. Sem. Nucl. Med., 2001, 31, 278-85.
18. Banerjee, S.R.; Maresca, K.P.; Francesconi, L.; Valliant, J.; Babich, J.W.; Zubieta, J. New Directions in the Coordination Chemistry of Tc-99m: A Reflection on Technetium Core Structures and a Strategy for New Chelate Design. Nucl. Med. Biol., 2005, 32, 1-20.
19. Meszaros, L.K.; Dose, A.; Biagini, S.C.G.; Blower, P.J. Hydrazinonicotinic Acid (Hynic) - Coordination Chemistry and Applications in Radiopharmaceutical Chemistry. Inorg. Chim. Acta, 2010, 363, 1059-69.
20. Woodward, S. Hsab Matching and Mismatching in Selective Catalysis and Synthesis. Tetrahedron, 2002, 58, 1017-50.
21. Combariza, M.Y.; Vachet, R.W. Gas-Phase Ion-Molecule Reactions of Transition Metal Complexes: The Effect of Different Coordination Spheres on Complex Reactivity. J. Am. Soc. Mass Spectr., 2002, 13, 813-25.
22. Crawford, P.; Hu, P. Reactivity of the 4d Transition Metals toward N Hydrogenation and Nh Dissociation: A Dft-Based Hsab Analysis. J. Phys. Chem. B, 2006, 110, 4157-61.
23. Chong, H.S.; Garmestani, K.; Ma, D.; Milenic, D.E.; Overstreet, T.; Brechbiel, M.W. Synthesis and Biological Evaluation of Novel Macrocyclic Ligands with Pendent Donor Groups as Potential Yttrium Chelators for Radioimmunotherapy with Improved Complex Formation Kinetics. J. Med. Chem., 2002, 45, 3458-64.
24. Chong, H.S.; Ma, X.; Le, T.; Kwamena, B.; Milenic, D.E.; Brady, E.D.; Song, H.A.; Brechbiel, M.W. Rational Design and Generation of a Bimodal Bifunctional Ligand for Antibody - Targeted Radiation Cancer Therapy. J. Med. Chem., 2008, 51, 118-25.
25. Chong, H.S.; Mhaske, S.; Lin, M.; Bhuniya, S.; Song, H.A.; Brechbiel, M.W.; Sun, X. Novel Synthetic Ligands for Targeted Pet Imaging and Radiotherapy of Copper. Bioorg. Med. Chem. Lett., 2007, 17, 6107-10.
26. Chong, H.S.; Song, H.A.; Ma, X.; Milenic, D.E.; Brady, E.D.; Lim, S.; Lee, H.; Baidoo, K.; Cheng, D.; Brechbiel, M.W. Novel Bimodal Bifunctional Ligands for Radioimmunotherapy and Targeted Mri. Bioconjug. Chem., 2008, 19, 1439-47.
27. Chong, H.S.; Lim, S.; Baidoo, K.E.; Milenic, D.E.; Ma, X.; Jia, F.; Song, H.A.; Brechbiel, M.W.; Lewis, M.R. Synthesis and Biological Evaluation of a Novel Decadentate Ligand Depa. Bioorg. Med. Chem. Lett., 2008, 18, 5792-5.
28. Hassfjell, S.; Brechbiel, M.W. The Development of the Alpha- Particle Emitting Radionuclides Bi-212 and Bi-213, and Their Decay Chain Related Radionuclides, for Therapeutic Applications. Chem. Rev., 2001, 101, 2019-36.
29. Miederer, M.; Scheinberg, D.A.; McDevitt, M.R. Realizing the Potential of the Actinium-225 Radionuclide Generator in Targeted Alpha Particle Therapy Applications. Adv. Drug Del. Rev., 2008, 60, 1371-82.
30. Song, H.; Hobbs, R.F.; Vajravelu, R.; Huso, D.L.; Esaias, C.; Apostolidis, C.; Morgenstern, A.; Sgouros, G. Radioimmunotherapy of Breast Cancer Metastases with Alpha-Particle Emitter Ac-225: Comparing Efficacy with Bi-213 and Y-90. Cancer Res., 2009, 69, 8941-8.
31. Pfost, B.; Seidl, C.; Autenrieth, M.; Saur, D.; Bruchertseifer, F.; Morgenstern, A.; Schwaiger, M.; Senekowitsch-Schmidtke, R. Intravesical Alpha-Radioimmunotherapy with Bi-213-Anti-Egfr- Mab Defeats Human Bladder Carcinoma in Xenografted Nude Mice. J. Nucl. Med., 2009, 50, 1700-8.
32. McDevitt, M.R.; Ma, D.S.; Simon, J.; Frank, R.K.; Scheinberg, D.A. Design and Synthesis of Ac-225 Radioimmunopharmaceuticals. Appl. Rad. Isotopes, 2002, 57, 841-7.
33. Li, Y.; Song, E.; Rizvi, S.M.A.; Power, C.A.; Beretov, J.; Raja, C.; Cozzi, P.J.; Morgenstern, A.; Apostolidis, C.; Allen, B.J.; Russell, P.J. Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models by (213)Bilabeled Multiple Targeted Alpha Radio immunoconjugates. Clin. Cancer Res., 2009, 15, 865-75.
34. Heppeler, A.; Froidevaux, S.; Mäcke, H.R.; Jerman, E.; Behe, M.; Powell, P.; Hennig, M. Radiometal-Labelled Macrocyclic Chelator- Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy. Chem. Eur. J., 1999, 5, 1974-81.
35. Fani, M.; Andre, J.P.; Maecke, H.R. Ga-68-Pet: A Powerful Generator-Based Alternative to Cyclotron-Based Pet Radiopharmaceuticals. Contr. Media Mol. Imag., 2008, 3, 53-63.
36. Bandoli, G.; Dolmella, A.; Tisato, F.; Porchia, M.; Refosco, F. Mononuclear Six-Coordinated Ga(III) Complexes: A Comprehensive Survey. Coord. Chem. Rev., 2009, 253, 56-77.
37. Harris, W.R.; Pecoraro, V.L. Thermodynamic Binding Constants for Gallium Transferrin. Biochem., 1983, 22, 292-9.
38. Ando, A.; Ando, I.; Hiraki, T.; Hisada, K. Relation between the Location of Elements in the Periodic Table and Various Organ- Uptake Rates. Nucl. Med. Biol., 1989, 16, 57-80.
39. Boros, E.; Ferreira, C.L.; Cawthray, J.F.; Price, E.W.; Patrick, B.O.; Wester, D.W.; Adam, M.J.; Orvig, C. Acyclic Chelate with Ideal Properties for (68)Ga Pet Imaging Agent Elaboration. J. Am. Chem. Soc., 2010, 132, 15726-33.
40. Gottschaldt, M.; Bohlender, C.; Pospiech, A.; Gorls, H.; Walther, M.; Muller, D.; Klette, I.; Baum, R.P.; Schubert, U.S. In-III and Ga-III Complexes of Sugar-Substituted Tripodal Trisalicylidene Imines: The First Ga-68-Labelled Sugar Derivative. Eur. J. Inorg. Chem., 2009, 4298-307.
41. Luyt, L.G.; Katzenellenbogen, J.A. A Trithiolate Tripodal Bifunctional Ligand for the Radiolabeling of Peptides with Gallium(III). Bioconjug. Chem., 2002, 13, 1140-5.
42. Gabriel, M.; Decristoforo, C.; Kendler, D.; Dobrozemsky, G.; Heute, D.; Uprimny, C.; Kovacs, P.; Von Guggenberg, E.; Bale, R.; Virgolini, I.J. Ga-68-Dota-Tyr(3)-Octreotide Pet in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and Ct. J. Nucl. Med., 2007, 48, 508-18.
43. Ambrosini, V.; Campana, D.; Tomassetti, P.; Grassetto, G.; Rubello, D.; Fanti, S. Pet/Ct with 68gallium-Dota-Peptides in Net: An Overview. Eur. J. Radiol., 2010.
44. Ujula, T.; Salomaki, S.; Virsu, P.; Lankinen, P.; Makinen, T.J.; Autio, A.; Yegutkin, G.G.; Knuuti, J.; Jalkanen, S.; Roivainen, A. Synthesis, 68ga Labeling and Preliminary Evaluation of Dota Peptide Binding Vascular Adhesion Protein-1: A Potential Pet Imaging Agent for Diagnosing Osteomyelitis. Nucl. Med. Biol., 2009, 36, 631-41.
45. Ujula, T.; Huttunen, M.; Luoto, P.; Perakyla, H.; Simpura, I.; Wilson, I.; Bergman, M.; Roivainen, A. Matrix Metalloproteinase 9 Targeting Peptides: Syntheses, 68ga-Labeling, and Preliminary Evaluation in a Rat Melanoma Xenograft Model. Bioconjug. Chem., 2010, 21, 1612-21.
46. Brom, M.; Oyen, W.J.; Joosten, L.; Gotthardt, M.; Boerman, O.C. 68ga-Labelled Exendin-3, a New Agent for the Detection of Insulinomas with Pet. Eur. J. Nucl. Med. Mol. Imag., 2010, 37, 1345-55.
47. Eisenwiener, K.P.; Prata, M.I.; Buschmann, I.; Zhang, H.W.; Santos, A.C.; Wenger, S.; Reubi, J.C.; Macke, H.R. Nodagatoc, a New Chelator-Coupled Somatostatin Analogue Labeled with [67/68ga] and [111in] for Spect, Pet, and Targeted Therapeutic Applications of Somatostatin Receptor (Hsst2) Expressing Tumors. Bioconjug. Chem., 2002, 13, 530-41.
48. Burchardt, C.; Riss, P.J.; Zoller, F.; Maschauer, S.; Prante, O.; Kuwert, T.; Roesch, F. [Ga-68]Ga-Do(2)a-(Obu-L-Tyr)(2): Synthesis, Ga-68-Radiolabeling and in vitro Studies of a Novel Ga-68-Do(2)a-Tyrosine Conjugate as Potential Tumor Tracer for Pet. Bioorg. Med. Chem. Lett., 2009, 19, 3498-501.
49. Mukai, T.; Suwada, J.; Sano, K.; Okada, M.; Yamamoto, F.; Maeda, M. Design of Ga-Dota-Based Bifunctional Radiopharmaceuticals: Two Functional Moieties Can Be Conjugated to Radiogallium-Dota without Reducing the Complex Stability. Bioorg. Med. Chem., 2009, 17, 4285-9.
50. Eder, M.; Krivoshein, A.V.; Backer, M.; Backer, J.M.; Haberkorn, U.; Eisenhut, M. Scvegf-Peg-Hbed-Cc and Scvegf-Peg-Nota Conjugates: Comparison of Easy-to-Label Recombinant Proteins for [Ga-68]Pet Imaging of Vegf Receptors in Angiogenic Vasculature. Nucl. Med. Biol., 2010, 37, 405-12.
51. Eder, M.; Wangler, B.; Knackmuss, S.; LeGall, F.; Little, M.; Haberkorn, U.; Mier, W.; Eisenhut, M. Tetrafluorophenolate of Hbed-Cc: A Versatile Conjugation Agent for Ga-68-Labeled Small Recombinant Antibodies. Eur. J. Nucl. Med. Mol. Imag., 2008, 35, 1878-86.
52. Clarke, E.T.; Martell, A.E. Stabilities of Trivalent Metal-Ion Complexes of the Tetraacetate Derivatives of 12-Membered, 13- Membered and 14-Membered Tetraazamacrocycles. Inorg. Chim. Acta, 1991, 190, 37-46.
53. Clarke, E.T.; Martell, A.E. Stabilities of the Fe(III), Ga(III) and In(III) Chelates of N,N',N''-Triazacyclononanetriacetic Acid. Inorg. Chim. Acta, 1991, 181, 273-80.
54. Andre, J.P.; Maecke, H.R.; Zehnder, M.; Macko, L.; Akyel, K.G. 1,4,7-Triazacyclononane-1-Succinic Acid-4,7-Diacetic Acid (Nodasa): A New Bifunctional Chelator for Radio Gallium- Labelling of Biomolecules. Chem. Comm., 1998, 1301-2.
55. Velikyan, I.; Maecke, H.; Langstrom, B. Convenient Preparation of 68ga-Based Pet-Radiopharmaceuticals at Room Temperature. Bioconjug. Chem., 2008, 19, 569-73.
56. Jeong, J.M.; Hong, M.K.; Chang, Y.S.; Lee, Y.S.; Kim, Y.J.; Cheon, G.J.; Lee, D.S.; Chung, J.K.; Lee, M.C. Preparation of a Promising Angiogenesis Pet Imaging Agent: 68ga-Labeled C(Rgdyk)-Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7- Triacetic Acid and Feasibility Studies in Mice. J. Nucl. Med., 2008, 49, 830-6.
57. Liu, Z.F.; Niu, G.; Wang, F.; Chen, X.Y. Ga-68-Labeled Nota- Rgd-Bbn Peptide for Dual Integrin and Grpr-Targeted Tumor Imaging. Eur. J. Nucl. Med. Mol. Imag., 2009, 36, 1483-94.
58. Boswell, C.A.; Regino, C.A.S.; Baidoo, K.E.; Wong, K.J.; Bumb, A.; Xu, H.; Milenic, D.E.; Kelley, J.A.; Lai, C.C.; Brechbiel, M.W. Synthesis of a Cross-Bridged Cyclam Derivative for Peptide Conjugation and Cu-64 Radiolabeling. Bioconjug. Chem., 2008, 19, 1476-84.
59. Sherry, A.D.; Brown, R.D.; Geraldes, C.F.G.; Koenig, S.H.; Kuan, K.T.; Spiller, M. Synthesis and Characterization of the Gadolinium (3+) Complex of Dota-Propylamide - a Model Dota-Protein Conjugate. Inorg. Chem., 1989, 28, 620-2.
60. Li, Z.B.; Chen, K.; Chen, X. (68)Ga-Labeled Multimeric Rgd Peptides for Micropet Imaging of Integrin Alpha(V)Beta (3) Expression. Eur. J. Nucl. Med. Mol. Imag., 2008, 35, 1100-8.
61. Notni, J.; Hermann, P.; Havlickova, J.; Kotek, J.; Kubicek, V.; Plutnar, J.; Loktionova, N.; Riss, P.J.; Rosch, F.; Lukes, I. A Triazacyclononane-Based Bifunctional Phosphinate Ligand for the Preparation of Multimeric 68ga Tracers for Positron Emission Tomography. Chem. Eur. J., 2010, 16, 7174-85.
62. Liu, S.; Pietryka, J.; Ellars, C.E.; Edwards, D.S. Comparison of Yttrium and Indium Complexes of Dota-Ba and Dota-Mba: Models for Y-90- and in-111-Labeled Dota-Biomolecule Conjugates. Bioconjug. Chem., 2002, 13, 902-13.
63. Rasaneh, S.; Rajabi, H.; Babaei, M.H.; Daha, F.J. Synthesis and Biodistribution Studies of Lu-177-Trastuzumab as a Therapeutic Agent in the Breast Cancer Mice Model. J. Label. Comp. Radiopharm., 2010, 53, 575-9.
64. Garrison, J.C.; Rold, T.L.; Sieckman, G.L.; Naz, F.; Sublett, S.V.; Figueroa, S.D.; Volkert, W.A.; Hoffman, T.J. Evaluation of the Pharmacokinetic Effects of Various Linking Group Using the in-111-Dota-X-Bbn(7-14)Nh2 Structural Paradigm in a Prostate Cancer Model. Bioconjug. Chem., 2008, 19, 1803-12.
65. Ahlgren, S.; Orlova, A.; Rosik, D.; Sandstrom, M.; Sjoberg, A.; Basstrup, B.; Widmark, O.; Fant, G.; Feldwisch, J.; Tolmachev, V. Evaluation of Maleimide Derivative of Dota for Site-Specific Labeling of Recombinant Affibody Molecules. Bioconjug. Chem., 2008, 19, 235-43.
66. Roosenburg, S.; Laverman, P.; Joosten, L.; Eek, A.; Oyen, W.J.G.; de Jong, M.; Rutjes, F.P.J.T.; van Delft, F.L.; Boerman, O.C. Stabilized in-111-Labeled Scck8 Analogues for Targeting Cck2- Receptor Positive Tumors: Synthesis and Evaluation. Bioconjug. Chem., 2010, 21, 663-70.
67. Miao, Y.; Benwell, K.; Quinn, T.P. 99mtc- and 111in-Labeled Alpha-Melanocyte-Stimulating Hormone Peptides as Imaging Probes for Primary and Pulmonary Metastatic Melanoma Detection. J. Nucl. Med., 2007, 48, 73-80.
68. Eisenwiener, K.P.; Powell, P.; Macke, H.R. A Convenient Synthesis of Novel Bifunctional Prochelators for Coupling to Bioactive Peptides for Radiometal Labelling. Bioorg. Med. Chem. Lett., 2000, 10, 2133-5.
69. Good, S.; Walter, M.A.; Waser, B.; Wang, X.J.; Muller-Brand, J.; Behe, M.P.; Reubi, J.C.; Maecke, H.R. Macrocyclic Chelator- Coupled Gastrin-Based Radiopharmaceuticals for Targeting of Gastrin Receptor-Expressing Tumours. Eur. J. Nucl. Med. Mol. Imag., 2008, 35, 1868-77.
70. Wicki, A.; Wild, D.; Storch, D.; Seemayer, C.; Gotthardt, M.; Behe, M.; Kneifel, S.; Mihatsch, M.J.; Reubi, J.C.; Macke, H.R.; Christofori, G. [Lys(40)(Ahx-Dtpa-in-111)Nh2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma. Clin. Cancer Res., 2007, 13, 3696-705.
71. de Visser, M.; Bernard, H.F.; Erion, J.L.; Schmidt, M.A.; Srinivasan, A.; Waser, B.; Reubi, J.C.; Krenning, E.P.; de Jong, M. Novel 111in-Labelled Bombesin Analogues for Molecular Imaging of Prostate Tumours. Eur. J. Nucl. Med. Mol. Imag., 2007, 34, 1228-38.
72. Orlova, A.; Rosik, D.; Sandstrom, M.; Lundqvist, H.; Einarsson, L.; Tolmachev, V. Evaluation of [(111/114m)in]Chx-a''-Dtpa- Zher2:342, an Affibody Ligand Coniugate for Targeting of Her2- Expressing Malignant Tumors. Q. J. Nucl. Med. Mol. Imag., 2007, 51, 314-23.
73. Tolmachev, V.; Xu, H.; Wallberg, H.; Ahlgren, S.; Nertman, M.; Sjoberg, A.; Sandstrom, M.; Abrahmsen, L.; Brechbiel, M.W.; Orlova, A. Evaluation of a Maleimido Derivative of Chx-a '' Dtpa for Site-Specific Labeling of Affibody Molecules. Bioconjug. Chem., 2008, 19, 1579-87.
74. Xu, H.; Baidoo, K.E.; Wong, K.J.; Brechbiel, M.W. A Novel Bifunctional Maleimido Chx-a '' Chelator for Conjugation to Thiol- Containing Biomolecules. Bioorg. Med. Chem. Lett., 2008, 18, 2679-83.
75. Wei, L.H.; Zhang, X.L.; Gallazzi, F.; Miao, Y.B.; Jin, X.F.; Brechbiel, M.W.; Xu, H.; Clifford, T.; Welch, M.J.; Lewis, J.S.; Quinn, T.P. Melanoma Imaging Using in-111-, Y-86- and Ga-68- Labeled Chx-a ''-Re(Arg(11))Ccmsh. Nucl. Med. Biol., 2009, 36, 345-54.
76. Clifford, T.; Boswell, C.A.; Biddlecombe, G.B.; Lewis, J.S.; Brechbiel, M.W. Validation of a Novel Chx-a'' Derivative Suitable for Peptide Conjugation: Small Animal Pet/Ct Imaging Using Yttrium-86-Chx-a''-Octreotide. J. Med. Chem., 2006, 49, 4297-304.
77. Watanabe, N.; Oriuchi, N.; Tanada, S.; Murata, H.; Inoue, T.; Kim, E.E.; Sasaki, Y.; Endo, K. Effect of Edetate Calcium Disodium on Yttrium-90 Activity in Bone of Mice. Ann. Nucl. Med., 1999, 13, 397-400.
78. Rosenblum, M.G.; Verschraegen, C.F.; Murray, J.L.; Kudelka, A.P.; Gano, J.; Cheung, L.; Kavanagh, J.J. Phase I Study of 90y- Labeled B72.3 Intraperitoneal Administration in Patients with Ovarian Cancer: Effect of Dose and Edta Coadministration on Pharmacokinetics and Toxicity. Clin. Cancer Res., 1999, 5, 953-61.
79. Pauwels, S.; Barone, R.; Walrand, S.; Borson-Chazot, F.; Valkema, R.; Kvols, L.K.; Krenning, E.P.; Jamar, F. Practical Dosimetry of Peptide Receptor Radionuclide Therapy with (90)Y-Labeled Somatostatin Analogs. J. Nucl. Med., 2005, 46 Suppl 1, 92S-8S.
80. Anderegg, G.; Arnaud-Neu, F.; Delgado, R.; Felcman, J.; Popov, K. Critical Evaluation of Stability Constants of Metal Complexes of Complexones for Biomedical and Environmental Applications. Pure Appl. Chem., 2008, 77, 1445-95.
81. Schlesinger, J.; Fischer, C.; Koezle, I.; Vonhoff, S.; Klussmann, S.; Bergmann, R.; Pietzsch, H.J.; Steinbach, J. Radiosynthesis of New [90Y]-Dota-Based Maleimide Reagents Suitable for the Prelabeling of Thiol-Bearing L-Oligonucleotides and Peptides. Bioconjug. Chem., 2009, 20, 1340-8.
82. Wängler, C.; Schirrmacher, R.; Bartenstein, P.; Wängler, B. Simple and Convenient Radiolabeling of Proteins Using a Prelabeling- Approach with Thiol-Dota. Bioorg. Med. Chem. Lett., 2009, 19, 1926-9.
83. Pietzsch, H.; Schlesinger, J.; Fischer, C.; Koezle, I.; Vonhoff, S.; Klussmann, S.; Bergmann, R.; Steinbach, J. Synthesis of New [Y-90]-Dota Based Maleimides for the Prelabeling of Thiol-Bearing LOligonucleotides and Peptides. J. Label. Comp. Radiopharm., 2009, 52, S491-S.
84. Brouwers, A.H.; van Eerd, J.E.; Frielink, C.; Oosterwijk, E.; Oyen, W.J.; Corstens, F.H.; Boerman, O.C. Optimization of Radioimmunotherapy of Renal Cell Carcinoma: Labeling of Monoclonal Antibody Cg250 with 131i, 90y, 177lu, or 186re. J. Nucl. Med., 2004, 45, 327-37.
85. Nayak, T.K.; Garmestani, K.; Baidoo, K.E.; Milenic, D.E.; Brechbiel, M.W. Preparation, Biological Evaluation, and Pharmacokinetics of the Human Anti-Her1 Monoclonal Antibody Panitumumab Labeled with 86y for Quantitative Pet of Carcinoma. J. Nucl. Med., 2010, 51, 942-50.
86. Lee, F.T.; Mountain, A.J.; Kelly, M.P.; Hall, C.; Rigopoulos, A.; Johns, T.G.; Smyth, F.E.; Brechbiel, M.W.; Nice, E.C.; Burgess, A.W.; Scott, A.M. Enhanced Efficacy of Radioimmunotherapy with 90y-Chx-a''-Dtpa-Hu3s193 by Inhibition of Epidermal Growth Factor Receptor (Egfr) Signaling with Egfr Tyrosine Kinase Inhibitor Ag1478. Clin. Cancer Res., 2005, 11, 7080s-6s.
87. Roselli, M.; Milenic, D.E.; Brechbiel, M.W.; Mirzadeh, S.; Pippin, C.G.; Gansow, O.A.; Colcher, D.; Schlom, J. In vivo Comparison of Chx-Dtpa Ligand Isomers in Athymic Mice Bearing Carcinoma Xenografts. Cancer Biother. Radiopharm., 1999, 14, 209-20.
88. Camera, L.; Kinuya, S.; Garmestani, K.; Wu, C.; Brechbiel, M.W.; Pai, L.H.; McMurry, T.J.; Gansow, O.A.; Pastan, I.; Paik, C.H.; et al. Evaluation of the Serum Stability and in vivo Biodistribution of Chx-Dtpa and Other Ligands for Yttrium Labeling of Monoclonal Antibodies. J. Nucl. Med., 1994, 35, 882-9.
89. Kumric, K.; Trtic-Petrovic, T.; Koumarianou, E.; Archimandritis, S.; Comor, J.J. Supported Liquid Membrane Extraction of Lu-177(III) with Dehpa and Its Application for Purification of Lu-177- Dota-Lanreotide. Sep. Purific. Techn., 2006, 51, 310-7.
90. Postema, E.J.; Frielink, C.; Oyen, W.J.G.; Raemaekers, J.M.M.; Goldenberg, D.M.; Corstens, F.H.M.; Boerman, O.C. Biodistribution of I-131-, Re-186-, Lu-177-, and Y-88-Labeled Hll2 (Epratuzumab) in Nude Mice with Cd22-Positive Lymphoma. Cancer Biother. Radiopharm., 2003, 18, 525-33.
91. Trtic-Petrovic, T.M.; Kumric, K.R.; Dordevic, J.S.; Vladisavljevic, G.T. Extraction of Lutetium(III) from Aqueous Solutions by Employing a Single Fibre-Supported Liquid Membrane. J. Separ. Sci., 2010, 33, 2002-9.
92. Li, W.P.; Ma, D.S.; Higginbotham, C.; Hoffman, T.; Ketring, A.R.; Cutler, C.S.; Jurisson, S.S. Development of an in vitro Model for Assessing the in vivo Stability of Lanthanide Chelates. Nucl. Med. Biol., 2001, 28, 145-54.
93. Rasaneh, S.; Rajabi, H.; Babaei, M.H.; Daha, F.J.; Salouti, M. Radiolabeling of Trastuzumab with Lu-177 Via Dota, a New Radiopharmaceutical for Radioimmunotherapy of Breast Cancer. Nucl. Med. Biol., 2009, 36, 363-9.
94. Koumarianou, E.; Mikolajczak, R.; Pawlak, D.; Zikos, X.; Bouziotis, P.; Garnuszek, P.; Karczmarczyk, U.; Maurin, M.; Archimandritis, S.C. Comparative Study on Dota-Derivatized Bombesin Analog Labeled with Y-90 and Lu-177: In vitro and in vivo Evaluation. Nucl. Med. Biol., 2009, 36, 591-603.
95. Linder, K.E.; Metcalfe, E.; Arunachalam, T.; Chen, J.Q.; Eaton, S.M.; Feng, W.W.; Fan, H.; Raju, N.; Cagnolini, A.; Lantry, L.E.; Nunn, A.D.; Swenson, R.E. In vitro and in vivo Metabolism of Lu- Amba, a Grp-Receptor Binding Compound, and the Synthesis and Characterization of Its Metabolites. Bioconjug. Chem., 2009, 20, 1171-8.
96. Tolmachev, V.; Orlova, A.; Pehrson, R.; Galli, J.; Baastrup, B.; Andersson, K.; Sandstrom, M.; Rosik, D.; Carlsson, J.; Lundqvist, H.; Wennborg, A.; Nilsson, F.Y. Radionuclide Therapy of Her2- Positive Microxenografts Using a Lu-177-Labeled Her2-Specific Affibody Molecule. Cancer Res., 2007, 67, 2773-82.
97. Kelly, M.P.; Lee, S.T.; Lee, F.T.; Smyth, F.E.; Davis, I.D.; Brechbiel, M.W.; Scott, A.M. Therapeutic Efficacy of Lu-177- Chx-a ''-Dtpa-Hu3s193 Radioimmunotherapy in Prostate Cancer Is Enhanced by Egfr Inhibition or Docetaxel Chemotherapy. Prostate, 2009, 69, 92-104.
98. Milenic, D.E.; Garmestani, K.; Chappell, L.L.; Dadachova, E.; Yordanov, A.; Ma, D.; Schlom, J.; Brechbiel, M.W. In vivo Comparison of Macrocyclic and Acyclic Ligands for Radiolabeling of Monoclonal Antibodies with 177lu for Radioimmunotherapeutic Applications. Nucl. Med. Biol., 2002, 29, 431-42.
99. Hens, M.; Vaidyanathan, G.; Zhao, X.G.; Bigner, D.D.; Zalutsky, M.R. Anti-Egfrviii Monoclonal Antibody Armed with Lu-177: In vivo Comparison of Macrocyclic and Acyclic Ligands. Nucl. Med. Biol., 2010, 37, 741-50.
100. Gasser, G.; Tjioe, L.; Graham, B.; Belousoff, M.J.; Juran, S.; Walther, M.; Kunstler, J.U.; Bergmann, R.; Stephan, H.; Spiccia, L. Synthesis, Copper(Ii) Complexation, Cu-64-Labeling, and Bioconjugation of a New Bis(2-Pyridylmethyl) Derivative of 1,4,7- Triazacyclononane. Bioconjug. Chem., 2008, 19, 719-30.
101. Bass, L.A.; Wang, M.; Welch, M.J.; Anderson, C.J. In vivo Transchelation of Copper-64 from Teta-Octreotide to Superoxide Dismutase in Rat Liver. Bioconjug. Chem., 2000, 11, 527-32.
102. Heroux, K.J.; Woodin, K.S.; Tranchemontagne, D.J.; Widger, P.C.B.; Southwick, E.; Wong, E.H.; Weisman, G.R.; Tomellini, S.A.; Wadas, T.J.; Anderson, C.J.; Kassel, S.; Golen, J.A.; Rheingold, A.L. The Long and Short of It: The Influence of NCarboxyethyl Versus N-Carboxymethyl Pendant Arms on in vitro and in vivo Behavior of Copper Complexes of Cross-Bridged Tetraamine Macrocycles. Dalton Trans., 2007, 2150-62.
103. Biddlecombe, G.B.; Rogers, B.E.; de Visser, M.; Parry, J.J.; de Jong, M.; Erion, J.L.; Lewis, J.S. Molecular Imaging of Gastrin- Releasing Peptide Receptor-Positive Tumors in Mice Using Cu-64- and Y-86-Dota-(Pro(1),Tyr(4))-Bombesin(1-14). Bioconjug. Chem., 2007, 18, 724-30.
104. Paudyal, P.; Paudyal, B.; Hanaoka, H.; Oriuchi, N.; Iida, Y.; Yoshioka, H.; Tominaga, H.; Watanabe, S.; Watanabe, S.; Ishioka, N.S.; Endo, K. Imaging and Biodistribution of Her2/Neu Expression in Non-Small Cell Lung Cancer Xenografts with 64Cu- Labeled Trastuzumab Pet. Cancer Sci., 2010, 101, 1045-50.
105. Jalilian, A.R.; Mirsadeghi, L.; Yari-Kamrani, Y.; Rowshanfarzad, P.; Kamali-Dehghan, M.; Sabet, M. Development of [Cu-64]-Dota- Anti-Cd20 for Targeted Therapy. Journal of Radioanalytical and Nuclear Chemistry, 2007, 274, 563-8.
106. Niu, G.; Li, Z.B.; Cao, Q.Z.; Chen, X.Y. Monitoring Therapeutic Response of Human Ovarian Cancer to 17-Dmag by Noninvasive Pet Imaging with Cu-64-Dota-Trastuzumab. Eur. J. Nucl. Med. Mol. Imag., 2009, 36, 1510-9.
107. Prasanphanich, A.F.; Nanda, P.K.; Rold, T.L.; Ma, L.; Lewis, M.R.; Garrison, J.C.; Hoffman, T.J.; Sieckman, G.L.; Figueroa, S.D.; Smith, C.J. [64cu-Nota-8-Aoc-Bbn(7-14)Nh2] Targeting Vector for Positron-Emission Tomography Imaging of Gastrin- Releasing Peptide Receptor-Expressing Tissues. Proc. Natl. Acad. Sci. U S A, 2007, 104, 12462-7.
108. Prasanphanich, A.F.; Retzloff, L.; Lane, S.R.; Nanda, P.K.; Sieckman, G.L.; Rold, T.L.; Ma, L.; Figueroa, S.D.; Sublett, S.V.; Hoffman, T.J.; Smith, C.J. In vitro and in vivo Analysis of [(64)Cu- No2a-8-Aoc-Bbn(7-14)Nh(2)]: A Site-Directed Radiopharmaceutical for Positron-Emission Tomography Imaging of T-47d Human Breast Cancer Tumors. Nucl. Med. Biol., 2009, 36, 171-81.
109. Liu, Z.; Yan, Y.; Liu, S.; Wang, F.; Chen, X. (18)F, (64)Cu, and (68)Ga Labeled Rgd-Bombesin Heterodimeric Peptides for Pet Imaging of Breast Cancer. Bioconjug. Chem., 2009, 20, 1016-25.
110. Liu, D.; Overbey, D.; Watkinson, L.D.; Smith, C.J.; Daibes-Figueroa, S.; Hoffman, T.J.; Forte, L.R.; Volkert, W.A.; Giblin, M.F. Comparative Evaluation of Three 64cu-Labeled E. Coli Heat-Stable Enterotoxin Analogues for Pet Imaging of Colorectal Cancer. Bioconjug. Chem., 2010, 21, 1171-6.
111. Christlieb, M.; Struthers, H.S.R.; Bonnitcha, P.D.; Cowley, A.R.; Dilworth, J.R. The Exocyclic Functionalisation of Bis(Thiosemicarbazonate) Complexes of Zinc and Copper: The Synthesis of Monomeric and Dimeric Species. Dalton Trans., 2007, 5043-54.
112. Yuan, H.; Schroeder, T.; Bowsher, J.E.; Hedlund, L.W.; Wong, T.; Dewhirst, M.W. Intertumoral Differences in Hypoxia Selectivity of the Pet Imaging Agent Cu-64(Ii)-Diacetyl-Bis(N-4-Methylthiosemicarbazone). J. Nucl. Med., 2006, 47, 989-98.
113. Bonnitcha, P.D.; Bayly, S.R.; Theobald, M.B.M.; Betts, H.M.; Lewis, J.S.; Dilworth, J.R. Nitroimidazole Conjugates of Bis(Thiosemicarbazonato)Cu-64(Ii) - Potential Combination Agents for the Pet Imaging of Hypoxia. J. Inorg. Biochem., 2010, 104, 126-35.
114. Holland, J.P.; Aigbirhio, F.I.; Betts, H.M.; Bonnitcha, P.D.; Burke, P.; Christlieb, M.; Churchill, G.C.; Cowley, A.R.; Dilworth, J.R.; Donnelly, P.S.; Green, J.C.; Peach, J.M.; Vasudevan, S.R.; Warren, J.E. Functionalized Bis(Thiosemicarbazonato) Complexes of Zinc and Copper: Synthetic Platforms toward Site-Specific Radiopharmaceuticals. Inorg. Chem., 2007, 46, 465-85.
115. Bayly, S.R.; King, R.C.; Honess, D.J.; Barnard, P.J.; Betts, H.M.; Holland, J.P.; Hueting, R.; Bonnitcha, P.D.; Dilworth, J.R.; Aigbirhio, F.I.; Christlieb, M. In vitro and in vivo Evaluations of a Hydrophilic Cu-64-Bis(Thiosemicarbazonato)-Glucose Conjugate for Hypoxia Imaging. J. Nucl. Med., 2008, 49, 1862-8.
116. Hueting, R.; Christlieb, M.; Dilworth, J.R.; Garayoa, E.G.; Gouverneur, V.; Jones, M.W.; Maes, V.; Schibli, R.; Sun, X.; Tourwe, D.A. Bis(Thiosemicarbazones) as Bifunctional Chelators for the Room Temperature 64-Copper Labeling of Peptides. Dalton Trans., 2010, 39, 3620-32.
117. Paterson, B.M.; Karas, J.A.; Scanlon, D.B.; White, J.M.; Donnelly, P.S. Versatile New Bis(Thiosemicarbazone) Bifunctional Chelators: Synthesis, Conjugation to Bombesin(7-14)-Nh2, and Copper-64 Radiolabeling. Inorg. Chem., 2010, 49, 1884-93.
118. Liang, X.; Sadler, P.J. Cyclam Complexes and Their Applications in Medicine. Chem. Soc. Rev., 2004, 33, 246-66.
119. McMurry, T.J.; Brechbiel, M.; Wu, C.; Gansow, O.A. Synthesis of 2-(P-Thiocyanatobenzyl)-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid: Application of the 4-Methoxy-2,3,6-Trimethylbenzenesulfonamide Protecting Group in the Synthesis of Macrocyclic Polyamines. Bioconjug. Chem., 1993, 4, 236-45.
120. Pandya, D.N.; Kim, J.Y.; Park, J.C.; Lee, H.; Phapale, P.B.; Kwak, W.; Choi, T.H.; Cheon, G.J.; Yoon, Y.R.; Yoo, J. Revival of Te2a; a Better Chelate for Cu(II) Ions Than Teta? Chem. Comm., 2010, 46, 3517-9.
121. Ramli, M.; Smith, S.V.; Lindoy, L.F. Investigation of Novel Bisand Tris-Tetraazamacrocycles for Use in the Copper-64 (Cu-64) Radiolabeling of Antibodies with Potential to Increase the Therapeutic Index for Drug Targeting. Bioconjug. Chem., 2009, 20, 868-76.
122. Galibert, M.; Jin, Z.H.; Furukawa, T.; Fukumura, T.; Saga, T.; Fujibayashi, Y.; Dumy, P.; Boturyn, D. Rgd-Cyclam Conjugate: Synthesis and Potential Application for Positron Emission Tomography. Bioorg. Med. Chem. Lett., 2010, 20, 5422-5.
123. Zimmermann, K.; Grunberg, J.; Honer, M.; Ametamey, S.; Schubiger, P.A.; Novak-Hofer, I. Targeting of Renal Carcinoma with (Cu)-C-67/64-Labeled Anti-L1-Cam Antibody Chce7: Selection of Copper Ligands and Pet Imaging. Nucl. Med. Biol., 2003, 30, 417-27.
124. Sprague, J.E.; Peng, Y.; Sun, X.; Weisman, G.R.; Wong, E.H.; Achilefu, S.; Anderson, C.J. Preparation and Biological Evaluation of Copper-64-Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator. Clin. Cancer Res., 2004, 10, 8674-82.
125. Wei, L.H.; Butcher, C.; Miao, Y.B.; Gallazzi, F.; Quinn, T.P.; Welch, M.J.; Lewis, J.S. Synthesis and Biologic Evaluation of Cu-64-Labeled Rhenium-Cyclized Alpha-Msh Peptide Analog Using a Cross-Bridged Cyclam Chelator. J. Nucl. Med., 2007, 48, 64-72.
126. Garrison, J.C.; Rold, T.L.; Sieckman, G.L.; Figueroa, S.D.; Volkert, W.A.; Jurisson, S.S.; Hoffman, T.J. In vivo Evaluation and Small-Animal Pet/Ct of a Prostate Cancer Mouse Model Using Cu-64 Bombesin Analogs: Side-by-Side Comparison of the Cb-Te2a and Dota Chelation Systems. J. Nucl. Med., 2007, 48, 1327-37.
127. Wei, L.; Ye, Y.; Wadas, T.J.; Lewis, J.S.; Welch, M.J.; Achilefu, S.; Anderson, C.J. Cu-64-Labeled Cb-Te2a and Diamsar- Conjugated Rgd Peptide Analogs for Targeting Angiogenesis: Comparison of Their Biological Activity. Nucl. Med. Biol., 2009, 36, 277-85.
128. Wadas, T.J.; Eiblmaier, M.; Zheleznyak, A.; Sherman, C.D.; Ferdani, R.; Liang, K.; Achilefu, S.; Anderson, C.J. Preparation and Biological Evaluation of Cu-64-Cb-Te2a-Sst(2)-Ant, a Somatostatin Antagonist for Pet Imaging of Somatostatin Receptor- Positive Tumors. J. Nucl. Med., 2008, 49, 1819-27.
129. Wadas, T.J.; Anderson, C.J. Radiolabeling of Teta- and Cb-Te2a- Conjugated Peptides with Copper-64. Nat. Protoc., 2006, 1, 3062-8.
130. Lewis, E.A.; Boyle, R.W.; Archibald, S.J. Ultrastable Complexes for in vivo Use: A Bifunctional Chelator Incorporating a Cross-Bridged Macrocycle. Chem. Comm., 2004, 2212-3.
131. Sun, X.K.; Wuest, M.; Weisman, G.R.; Wong, E.H.; Reed, D.P.; Boswell, C.A.; Motekaitis, R.; Martell, A.E.; Welch, M.J.; Anderson, C.J. Radiolabeling and in vivo Behavior of Copper-64-Labeled Cross-Bridged Cyclam Ligands. J. Med. Chem., 2002, 45, 469-77.
132. Boswell, C.A.; Sun, X.; Niu, W.; Weisman, G.R.; Wong, E.H.; Rheingold, A.L.; Anderson, C.J. Comparative in vivo Stability of Copper-64-Labeled Cross-Bridged and Conventional Tetraazamacrocyclic Complexes. J. Med. Chem., 2004, 47, 1465-74.
133. Woodin, K.S.; Heroux, K.J.; Boswell, C.A.; Wong, E.H.; Weisman, G.R.; Niu, W.J.; Tomellini, S.A.; Anderson, C.J.; Zakharov, L.N.; Rheingold, A.L. Kinetic Inertness and Electrochemical Behavior of Copper(II) Tetraazamacrocyclic Complexes: Possible Implications for in vivo Stability. Eur. J. Inorg. Chem., 2005, 4829-33.
134. Cai, H.C.; Li, Z.B.; Huang, C.W.; Park, R.; Shahinian, A.H.; Conti, P.S. An Improved Synthesis and Biological Evaluation of a New Cage-Like Bifunctional Chelator, 4-((8-Amino-3,6,10,13,16,19-Hexaazabicyclo[6.6.6]Icosane-1-Ylamino)Methyl)Benzoic Acid, for Cu-64 Radiopharmaceuticals. Nucl. Med. Biol., 2010, 37, 57-65.
135. Cai, H.; Fissekis, J.; Conti, P.S. Synthesis of a Novel Bifunctional Chelator Ambasar Based on Sarcophagine for Peptide Conjugation and (64)Cu Radiolabelling. Dalton. Trans., 2009, 5395-400.
136. Di Bartolo, N.; Sargeson, A.M.; Smith, S.V. New 64cu Pet Imaging Agents for Personalised Medicine and Drug Development Using the Hexa-Aza Cage, Sarar. Org. Biomol. Chem., 2006, 4, 3350-7.
137. Cai, H.C.; Li, Z.B.; Huang, C.W.; Shahinian, A.H.; Wang, H.; Park, R.; Conti, P.S. Evaluation of Copper-64 Labeled Ambasar Conjugated Cyclic Rgd Peptide for Improved Micropet Imaging of Integrin Alpha(V)Beta(3) Expression. Bioconjug. Chem., 2010, 21, 1417-24.
138. Dearling, J.; Voss, S.; Dunning, P.; Snay, E.; Fahey, F.; Smith, S.; Huston, J.; Meares, C.; Treves, S.; Packard, A. Imaging Cancer Using Pet - the Effect of the Bifunctional Chelator on the Biodistribution of a 64Cu-Labeled Antibody. Nucl. Med. Biol., 2010, In Press.